The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
Jason Chew- Chief Scientific Analyst
Jason Chew is a graduate of the University of California at Berkeley with over 10 years of experience as a scientist at leading biotech companies. He is a published author in a peer-reviewed scientific journal and has worked with Accenture thought leaders to develop new strategies for innovation in the pharmaceutical industry. He has blogged on a variety of industry topics and covered the industry as a freelance journalist. Jason was most recently contributing editor at the biotechnology newsletter CurrinResearch.com.
Patrick Crutcher- Chief Research Analyst
Patrick Crutcher is a statistical consultant, PhD candidate at UCLA, and a biotech blogger. He has blogged on a range of topics, including oncology, biosimilars, and hematology. He utilizes his background in statistics to identify attractive investment opportunities in biotechnology and healthcare. Previously, Patrick worked on the development of quantitative financial models for several financial institutions. He has an M.S in Statistics from UCLA and a B.S. in Mathematics from the University of Illinois. Patrick is currently working on a PhD in Statistics at UCLA.
Dr. Andrew Goodwin- Research Analyst
Andrew Goodwin, PhD is the founder and Editor-in-Chief of BiotechDueDiligence, a blog and website dedicated to educating biotech investors and enthusiasts. After ten years of academic biomedical research, including a postdoctoral fellowship and faculty appointment at the Johns Hopkins University School of Medicine, Andrew now serves as a Pharmacologist at the Food and Drug Administration (FDA). He is a graduate of The College of William and Mary and earned a PhD in Cellular and Molecular Medicine from Johns Hopkins. Andrew is an author of nine book chapters and peer-reviewed journal articles, including publications in the Proceedings of the National Academy of Science (PNAS) and Cancer Research.
Dr. Tro Kalayjian- Chief Medical Analyst
Dr. Tro Kalayjian is currently the incoming Chief Resident at Greenwich Hospital, in an Internal Medicine Residency Program. He has worked on several clinical research projects, including; a systemic review comparing treatment options for neuropathic pain, and a clinical trial that sought to establish a relationship between post-exercise ABI and a positive nuclear stress test. .
Tro was a contributing writer for Seeking Alpha from 2008 to 2011, and has been recognized as an Opinion Leader in the Healthcare Sector. In 2012, he was named one of the Top 50 voices in biotech by Fierce Markets. His past work experience also includes research services management for the Smilow Research Center at New York University Medical Center and for the Departments of Biology and Chemistry at New York University. His work experience also includes buy-side analysis for a small, New Jersey-based hedge fund.
- CEO and Trading Analyst
Tony Pelz was a trader on a major European bank’s proprietary trading desk. He was responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Mr. Pelz worked with several major investment banks in roles ranging from corporate finance, mergers and acquisitions to credit and business development. He has substantial international work experience in Asia, U.S., Europe and Latin America and was based in New York City, Bogotá (Colombia), Rio de Janeiro (Brazil) and Amsterdam (The Netherlands). Mr. Pelz currently resides in Denver, Colorado where he trades for his own account.
Dr. Juan Pedro Rodríguez Serrate
- Research Analyst
Juan Pedro Rodríguez Serrate holds a doctoral degree in Veterinary Science and a Master’s degree in Biotechnology. He completed a period of training as a research fellow with the Yale University School of Medicine where he studied the proposed causative agent of the Creutzfeldt-Jakob disease and other Transmissible Spongiform Encephalopathies in a basic research lab.
Over the last six years he has been working as a tech transfer and business development manager for one of the most dynamic public bodies in Spain dedicated to biotech. He manages a seed capital fund that invests in very early stage projects such as start-ups and development-oriented projects arising from public institutions. This fund has invested more than €9 million over the last 7 years, raising an additional €37m from public and private sources. It has successfully transferred 17 projects to the market.
- Trading Analyst
Joe Gantoss holds a Business Administration degree in Computer Science. He has held several executive positions in some of the largest technology companies in Israel. In the late 1990’s, Mr. Gantoss started his career as an equity trader, specializing in the US markets and Forex trading. In the late 2000’s, Mr. Gantoss shifting his trading focus to biotechnology and pharmaceuticals. During this time, Mr. Gantoss has not only succeeded as a full-time trader, but also as a Contributor and Analyst for Seeking Alpha, BiotechCharts.com, BioHolder.com and on his own personal blog.
Mr. Gantoss strategy is well known for it’s emphasis on technical analysis, with particular focus on Japanese Candlestick techniques. Mr. Gantoss uses fundamental analysis and thorough due diligence, to determine the best entry and exit points around clinical and regulatory catalysts. Mr. Gantoss has a strong following on Twitter, StockTwits, and Chart.ly.
Dr. David Sobek
- Research Analyst
David Sobek has been writing on biotech for more than 3 years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvania State University in 2003 and a BA in international relations from The College of William and Mary in 1997. He has been a contributor to Seeking Alpha and currently writes a weekly biotech column for TheStreet.Com.